Payment overview · 2025
General Payments
$381.25
18 reported records · 13 companies
Healthcare provider profile · identity verified
Ernest Sidney White, MD
Allopathic & Osteopathic Physicians|Family Medicine · PARIS, TX · NPI 1295748283
Verified facts
What the public records show
CMS Open Payments records show Ernest Sidney White, MD received $381.25 in general payments during 2025 across 18 reported records.
GlaxoSmithKline, LLC. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.70 | 15.9% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $58.55 | 15.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $44.49 | 11.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.98 | 10.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.72 | 8.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.78 | 6.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.25 | 5.0% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $18.63 | 4.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.19 | 4.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.13 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.05 | 4.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.71 | 4.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.07 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $381.25 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.70 | 3 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $58.55 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $44.49 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 465 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 305 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 75 |
| Gabapentin | Gabapentin | 236 | 69 |
| Omeprazole | Omeprazole | 199 | 47 |
| Metformin Hcl | Metformin Hcl | 185 | 63 |
| Farxiga | Dapagliflozin Propanediol | 167 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 33 |
| Potassium Chloride | Potassium Chloride | 131 | 27 |
| Ezetimibe | Ezetimibe | 130 | 32 |
| Lisinopril | Lisinopril | 125 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 29 |
| Losartan Potassium | Losartan Potassium | 121 | 38 |
| Meloxicam | Meloxicam | 121 | 33 |
| Glimepiride | Glimepiride | 119 | 24 |
| Furosemide | Furosemide | 117 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 22 |
| Spironolactone | Spironolactone | 97 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 24 |
| Prednisone | Prednisone | 82 | 44 |
| Allopurinol | Allopurinol | 79 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 23 |
| Jardiance | Empagliflozin | 73 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 21 |
| Alendronate Sodium | Alendronate Sodium | 70 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 11 |
| Tramadol Hcl | Tramadol Hcl | 68 | 25 |
| Sertraline Hcl | Sertraline Hcl | 66 | 17 |
| Torsemide | Torsemide | 66 | 15 |
| Trazodone Hcl | Trazodone Hcl | 64 | 15 |
| Carvedilol | Carvedilol | 63 | 22 |
| Pregabalin | Pregabalin | 58 | 11 |
| Eliquis | Apixaban | 56 | 11 |
| Ozempic | Semaglutide | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 16 |
| Topiramate | Topiramate | 54 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Azithromycin | Azithromycin | 51 | 40 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 48 | suppressed |
| Simvastatin | Simvastatin | 47 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 18 |
| Bumetanide | Bumetanide | 44 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 20 |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 27 |
| Temazepam | Temazepam | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 18 |
| Invokana | Canagliflozin | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 17 |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $381.25 · 18 records | GlaxoSmithKline, LLC. | AMYVID, AREXVY, CAPLYTA, Cologuard Collection Kit, Epclusa, GVOKE HYPOPEN, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, KISUNLA, Korlym, NURTEC ODT, PIFELTRO, TRELEGY ELLIPTA, VOQUEZNA, YUPELRI, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error